Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ADRB1	153	PHENYLPROPANOLAMINE	CHEMBL61006	agonist	DrugBank	1722692, 2881994
ADRB1	153	LOXAPINE	CHEMBL831	binder	DrugBank
ADRB1	153	PROPRANOLOL	CHEMBL27	antagonist	TdgClinicalTrial, TEND, DrugBank	17572694, 15236843, 11752352, 14757703, 17628611, 16177222
ADRB1	153	MEPHENTERMINE	CHEMBL1201234	agonist	DrugBank	21182601
ADRB1	153	CLENBUTEROL	CHEMBL49080	agonist	DrugBank	20590599
ADRB1	153	OXPRENOLOL	CHEMBL546	antagonist	TdgClinicalTrial, TEND, DrugBank, TTD	6124492, 17139284, 17016423, 6202960, 11752352, 2871880
ADRB1	153	DRONEDARONE	CHEMBL184412		TdgClinicalTrial, TEND, DrugBank	17389667
ADRB1	153	BUFURALOL	CHEMBL296035	antagonist	DrugBank	37605
ADRB1	153	ISOPROTERENOL	CHEMBL434		PharmGKB, TdgClinicalTrial, TEND
ADRB1	153	BETAXOLOL	CHEMBL423	antagonist	TdgClinicalTrial, TEND, TTD
ADRB1	153	AMIODARONE	CHEMBL633		TdgClinicalTrial, TEND
ADRB1	153	METOPROLOL	CHEMBL13		TdgClinicalTrial, TEND
ADRB1	153	TIMOLOL	CHEMBL499	antagonist	TdgClinicalTrial, ChemblInteractions, TEND
ADRB1	153	SOTALOL HYDROCHLORIDE	CHEMBL1700	antagonist	ChemblInteractions
ADRB1	153	NEBIVOLOL HYDROCHLORIDE	CHEMBL1201731	antagonist	ChemblInteractions
ADRB1	153	CARTEOLOL HYDROCHLORIDE	CHEMBL1201002	antagonist	ChemblInteractions
ADRB1	153	BETHANIDINE	CHEMBL1201260	antagonist	DrugBank	11752352, 6114720, 6812406
ADRB1	153	PINDOLOL	CHEMBL500	partial agonist	TdgClinicalTrial, ChemblInteractions, TEND, DrugBank	1687398, 11752352, 14608456, 2907348, 2148726, 8884690
ADRB1	153	ISOPRENALINE	CHEMBL1160723	agonist	DrugBank	14734046, 16038799, 15908512, 11752352, 10722
ADRB1	153	ARBUTAMINE	CHEMBL1201251	agonist	TdgClinicalTrial, TEND, DrugBank	8723169, 17139284, 17016423
ADRB1	153	NADOLOL	CHEMBL649	antagonist	TdgClinicalTrial, ChemblInteractions, TEND, DrugBank	10433496, 11752352, 1354084, 7912539, 7981009, 10606440
ADRB1	153	PRACTOLOL	CHEMBL6995	antagonist	TdgClinicalTrial, TEND, DrugBank, TTD	2857116, 30388, 2871880, 6524278, 11752352
ADRB1	153	NEBIVOLOL	CHEMBL434394	antagonist	TdgClinicalTrial, TEND, DrugBank, TTD	11752352, 17661735, 16961165
ADRB1	153	DROXIDOPA	CHEMBL2103827	agonist	ChemblInteractions, DrugBank	18064417, 9464897, 19110970
ADRB1	153	BOPINDOLOL	CHEMBL357995	partial agonist	DrugBank	1687398, 11752352, 14608456, 2907348, 2148726, 8884690
ADRB1	153	BISOPROLOL	CHEMBL645	antagonist	TdgClinicalTrial, TEND, TTD
ADRB1	153	DOBUTAMINE	CHEMBL926	agonist	TdgClinicalTrial, TEND, TTD
ADRB1	153	LEVOBETAXOLOL	CHEMBL1201274	antagonist	TTD
ADRB1	153	MURAGLITAZAR	CHEMBL186179		PharmGKB
ADRB1	153	SOTALOL	CHEMBL471	antagonist	TTD
ADRB1	153	ESMOLOL	CHEMBL768	antagonist	TdgClinicalTrial, TEND, TTD
ADRB1	153	MEPHENTERMINE SULFATE	CHEMBL1200996	agonist	ChemblInteractions
ADRB1	153	OXPRENOLOL HYDROCHLORIDE	CHEMBL1200745	antagonist	ChemblInteractions
ADRB1	153	BISOPROLOL FUMARATE	CHEMBL1200708	antagonist	ChemblInteractions
ADRB1	153	METIPRANOLOL HYDROCHLORIDE	CHEMBL1200947	antagonist	ChemblInteractions
ADRB1	153	PENBUTOLOL SULFATE	CHEMBL1200363	antagonist	ChemblInteractions
ADRB1	153	BETAXOLOL HYDROCHLORIDE	CHEMBL1691	antagonist	ChemblInteractions
ADRB1	153	TIMOLOL MALEATE	CHEMBL1200870	antagonist	ChemblInteractions
ADRB1	153	ISOPROTERENOL SULFATE	CHEMBL1200447	agonist	ChemblInteractions
ADRB1	153	METOPROLOL FUMARATE	CHEMBL1200898	antagonist	ChemblInteractions
ADRB1	153	ACEBUTOLOL HYDROCHLORIDE	CHEMBL1200813	antagonist	ChemblInteractions
ADRB1	153	PROPAFENONE HYDROCHLORIDE	CHEMBL1201063	antagonist	ChemblInteractions
ADRB1	153	ALPRENOLOL	CHEMBL266195	antagonist	TdgClinicalTrial, TEND, DrugBank, TTD	10433496, 12522078, 11752352, 2828119, 7678677, 7606348
ADRB1	153	CARVEDILOL	CHEMBL723	antagonist	TdgClinicalTrial, ChemblInteractions, TEND, DrugBank	1712335, 7908256, 2575762, 2577144
ADRB1	153	PIRBUTEROL	CHEMBL1094966	agonist	DrugBank	6143816, 2901958
ADRB1	153	BEVANTOLOL	CHEMBL314010	antagonist	TdgClinicalTrial, TEND, DrugBank	2888789, 17628611, 6148733, 2858236, 2568629
ADRB1	153	CELIPROLOL	CHEMBL27810	antagonist	DrugBank	17141277, 17384462, 18636069
ADRB1	153	VORTIOXETINE	CHEMBL2104993	ligand	DrugBank	21486038
ADRB1	153	BUDIODARONE	CHEMBL2105631		TdgClinicalTrial
ADRB1	153	LABETALOL	CHEMBL429		TdgClinicalTrial, TEND
ADRB1	153	DOBUTAMINE HYDROCHLORIDE	CHEMBL1200418	agonist	ChemblInteractions
ADRB1	153	NORADRENALINE	CHEMBL1356607	agonist	ChemblInteractions
ADRB1	153	LY377604	CHEMBL2012520	antagonist	ChemblInteractions
ADRB1	153	DOPAMINE HYDROCHLORIDE	CHEMBL1557	agonist	ChemblInteractions
ADRB1	153	METOPROLOL TARTRATE	CHEMBL1256957	antagonist	ChemblInteractions
ADRB1	153	ISOPROTERENOL HYDROCHLORIDE	CHEMBL1711	agonist	ChemblInteractions
ADRB1	153	NOREPINEPHRINE	CHEMBL1437	agonist	PharmGKB, DrugBank	11752352, 18064417, 9464897, 19110970
ADRB1	153	ISOETHARINE	CHEMBL1201213	agonist	TdgClinicalTrial, TEND, DrugBank	16973691, 17628611, 17329986, 15917856, 17157779
ADRB1	153	ATENOLOL	CHEMBL24	antagonist	TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD	11752352, 17628611, 12065078, 10913016, 9300315
ADRB1	153	MIRTAZAPINE	CHEMBL654	binder	DrugBank	10762339
ADRB1	153	LEVOBUNOLOL	CHEMBL1201237	antagonist	TdgClinicalTrial, TEND, DrugBank	2891463, 2892662, 11572462, 7928182, 1351412, 10864881
ADRB1	153	METIPRANOLOL	CHEMBL1291	antagonist	TdgClinicalTrial, TEND, DrugBank	2885244, 2895037, 17139284, 17016423, 12967722
ADRB1	153	PENBUTOLOL	CHEMBL1290	partial agonist, antagonist	TdgClinicalTrial, TEND, DrugBank	2189902, 11224195, 6755764, 11738481
ADRB1	153	EPINEPHRINE	CHEMBL679	agonist	TdgClinicalTrial, ChemblInteractions, TEND
ADRB1	153	ZIPRASIDONE	CHEMBL708		TEND
ADRB1	153	BUCINDOLOL	CHEMBL321582		PharmGKB, TdgClinicalTrial
ADRB1	153	CARTEOLOL	CHEMBL839		TdgClinicalTrial, TEND
ADRB1	153	DESIPRAMINE	CHEMBL72		TdgClinicalTrial, TEND
ADRB1	153	ACEBUTOLOL	CHEMBL642	antagonist	TdgClinicalTrial, TEND, TTD
ADRB1	153	DOPAMINE	CHEMBL59		PharmGKB
ADRB1	153	DIPIVEFRIN HYDROCHLORIDE	CHEMBL1200833	agonist	ChemblInteractions
ADRB1	153	LEVOBETAXOLOL HYDROCHLORIDE	CHEMBL1200837	antagonist	ChemblInteractions
ADRB1	153	METOPROLOL SUCCINATE	CHEMBL1200337	antagonist	ChemblInteractions
ADRB1	153	LABETALOL HYDROCHLORIDE	CHEMBL1200323	antagonist	ChemblInteractions
ADRB1	153	LEVOBUNOLOL HYDROCHLORIDE	CHEMBL1201177	antagonist	ChemblInteractions
ADRB1	153	EPINEPHRINE BITARTRATE	CHEMBL1256958	agonist	ChemblInteractions
ADRB1	153	HYDROXYAMPHETAMINE HYDROBROMIDE	CHEMBL1200705	agonist	ChemblInteractions
ADRB1	153	PROPRANOLOL HYDROCHLORIDE	CHEMBL1671	antagonist	ChemblInteractions
ADRB1	153	CARVEDILOL PHOSPHATE	CHEMBL1201167	antagonist	ChemblInteractions
ADRB1	153	ESMOLOL HYDROCHLORIDE	CHEMBL1201115	antagonist	ChemblInteractions
ADRB1	153	CABERGOLINE	CHEMBL1201087	binder	DrugBank	12388666
ADRB1	153	OLANZAPINE	CHEMBL715		DrugBank	8822531
ADRB1	153	AMPHETAMINE	CHEMBL405	agonist	DrugBank	4399738, 6245760
ADRB1	153	FENOTEROL	CHEMBL32800	agonist	DrugBank	14730417
ADRB1	153	BUPRANOLOL	CHEMBL305380	antagonist	DrugBank	19439807

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ADRB1	rs1801253	C	metoprolol	efficacy	yes	The CC (Arg389) homozygous genotype was strongly associated with the DBP response to metoprolol with a significantly greater reduction in 24-hour and daytime DBP than was found in carriers of a G(Gly389) allele.	Allele C is associated with increased response to metoprolol in people with Hypertension as compared to allele G.	12844134	748396572
ADRB1	rs1801252	A	Beta Blocking Agents	efficacy	no		Allele A is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.	15861037	613979010
ADRB1	rs1801253	C	Beta Blocking Agents	efficacy	no		Allele C is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.	15861037	613979015
ADRB1	rs1801252	AA	bisoprolol	efficacy	yes		Genotype AA is not associated with increased response to bisoprolol in people with Hypertension.	20300048	655387637
ADRB1	rs1801253	CC	metoprolol	efficacy	not stated	Increased response to metoprolol was defined by a greater decrease in heart rate and systolic blood pressure in the CC subjects than in the GG genotype subjects. All subjects were Ser49 (rs1801252) homozygous.	Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotype GG.	14534524	827567343
ADRB1	rs1801253	G	hydrochlorothiazide	efficacy	no		Allele G is not associated with response to hydrochlorothiazide in people with Essential hypertension as compared to allele C.	14553962	827921276
ADRB1	rs1801253	CG + GG	metoprolol	efficacy	no	Where dose is the median dose per day in mg.	Genotypes CG + GG are not associated with dose of metoprolol in people with Heart Failure as compared to genotype CC.	20643254	982045253
ADRB1	rs1801253	CC	metoprolol	efficacy	yes	This SNP was studied in conjunction with rs61767072, in the ADRA2C gene. When treated with metoprolol, patients that had Arg389Arg/del-carrier genotypes had a significantly greater increase in ejection fraction as compared to patients with any other genotype (Arg389Arg/Ins/Ins, Gly389-carrier/del-carrier, or Gly389-carrier/Ins/Ins). The authors also suggest that the ADRB1 polymorphism is less strongly associated with the level of sympathetic nervous system activation than the ADRA2C polymorphism.	Genotype CC is associated with increased response to metoprolol in people with Heart Failure as compared to genotypes CG + GG.	17496726	981477795
ADRB1	rs1801253	CC	dobutamine	efficacy	yes	Healthy male individuals with the CC genotype had a greater increase in fractional shortening (FS) after cumulative doses of dobutamine, compared to G allele carriers. Response in FS was compared by calculating the area under the curve (AUC) of the dose-response relationship of GG and GC+CC. The AUC of the dose-response curves for GG and GC+CC were significantly different.	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.	15564877	982034981
ADRB1	rs1801253	CC	carvedilol	efficacy	no	No significant differences in percent change in left ventricular ejection fraction between genotypes was seen. Percent differences calculated between baseline and 12 months of treatment.	Genotype CC is not associated with response to carvedilol in people with Heart Failure as compared to genotypes CG + GG.	20352314	982044019
ADRB1	rs1801253	CC	dobutamine	efficacy	yes	Patients with the CC genotype had significantly greater increases in systolic blood pressure (mmHg) upon cumulative doses of dobutamine, compared to carriers of the G allele. Dobutamine was given as a continuous infusion of increasing doses: 10, 20, 30 and 40 ug/kg/min. Significant differences in systolic blood pressure between genotypes were seen at 30 and 40 ug/kg/min doses only.	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.	15564877	982035028
ADRB1	rs1801253	CC	catecholamines	dosage	yes	This SNP was presented as ADRB1 Arg389Gly. Patients with low cardiac index (CI) after undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass were given adrenaline as positive inotropic support. Patients homozygous for the Arg allele needed significantly less, and a shorter duration of, adrenaline administration to reach a stable CI as compared to Gly homozygous individuals. Heterozygous patients needed an intermediate dose.	Genotype CC is associated with decreased dose of catecholamines in people with Coronary Artery Disease as compared to genotypes CG + GG.	17541557	1043859264
ADRB1	rs1801253	CC	bucindolol	efficacy	yes	This SNP was mainly referred to as an Arg>Gly amino acid change at position 389, with the Arg amino acid resulting in better patient outcome. This study was interested in the effect of this SNP in tandem with rs61767072. Patients homozygous for the Arg amino acid showed significantly less occurrences of all cause mortality, cardiac transplant, or heart failure hospitalizations as compared to other patients. Patients carrying the Gly amino acid but were homozygous for the wildtype allele at rs61767072 responded worse than those that were homozygous for wildtype allele at this SNP, but much better than patients carrying the variant allele at both SNPs. Patients carrying the variant allele at both SNPs and were treated with bucindolol had worse outcomes than those that were given a placebo.	Genotype CC is associated with increased response to bucindolol in people with Heart Failure as compared to genotypes CG + GG.	23071495	982046368
ADRB1	rs1801253	CC	bisoprolol	dosage	no	The average administered dose of bisoprolol per day of treatment did not differ between genotypes, in patients with heart disease undergoing surgery using spinal block.	Genotype CC is not associated with dose of bisoprolol in people with Coronary Artery Disease as compared to genotypes CG + GG.	17585213	982044110
ADRB1	rs1801253	CC	dobutamine	efficacy	no	No significant differences in heart rate were seen between the CC genotype and G allele carriers, upon cumulative doses of dobutamine. Dobutamine was given as a continuous infusion of increasing doses: 10, 20, 30 and 40 ug/kg/min.	Genotype CC is not associated with response to dobutamine in healthy individuals as compared to genotypes CG + GG.	15564877	982035057
ADRB1	rs1801253	GG	carvedilol	dosage	yes	Where dose is the median dose per day in mg.	Genotype GG is associated with increased dose of carvedilol in people with Heart Failure as compared to genotype CC.	20643254	982045173
ADRB1	rs1801253	C	atenolol	efficacy	yes	Either alone as a SNP or in combination with rs1801252 allele A as a haplotype. Neither this SNP nor any haplotype combination (haplotypes AG and GC were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown).	Allele C is not associated with response to atenolol in people with Essential hypertension.	20235788	982044875
ADRB1	rs1801253	CG + GG	carvedilol	efficacy	no	No significant association was seen between genotype and response to the drugs. Patients had to fulfill 3 of 5 criteria in order to be classified as a responder - these criteria can be found in the paper. Patients were treated for 14 months.	Genotypes CG + GG are not associated with response to carvedilol or metoprolol in people with Heart Failure as compared to genotype CC.	20643254	982045219
ADRB1	rs1801253	C	citalopram	efficacy	no	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (CC, CG, GG) or the alleles (C, G), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	Allele C is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.	18797399	1184749213
ADRB1	rs1801253	CC	dobutamine	efficacy	yes	Response defined as heart rate and renin responses to dobutamine. In a multi-variant analysis genotype was an significant contributor to change in heart rate (p=0.011). ADRB1 Arg389 homozygous had a three-fold greater response in heart rate and renin response compared with Gly389 homozygotes.	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotype GG.	26313487	1446895961
ADRB1	rs1801252	G	atenolol	efficacy	no	No significant association between this variant and response to atenolol or metoprolol, as measured by changes in heart rate, in black or white patients.	Allele G is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele A.	31090079	1451107160
ADRB1	rs1801253	C	atenolol	efficacy	no	No significant association between this variant and response to atenolol or metoprolol, as measured by changes in heart rate, in black or white patients.	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.	31090079	1451107261
ADRB1	rs1801252	AG + GG	atenolol	efficacy	no	Reported as 52% responders in carriers of minor allele group vs. 55% in Ser49Ser. Ser corresponds to A on the + strand. [stat_test:chi square].	Genotypes AG + GG are not associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype AA.	22192668	827816346
ADRB1	rs1801252	A	atenolol	efficacy	yes	Either alone as a SNP or in combination with rs1801253 allele C as a haplotype. Neither this SNP nor any haplotype combination (haplotypes AG and GC were also present in the population) predicted systolic blood pressure or diastolic blood pressure response to atenolol after 4 or 8 weeks of treatment, either in the combined cohort or after sex stratification (data was not shown).	Allele A is not associated with response to atenolol in people with Essential hypertension.	20235788	655387640
ADRB1	rs1801252	G	carvedilol	efficacy	yes	"The ADRB1 Gly49 allele was associated with higher baseline heart rates. Carvedilol-induced reduction of exercise heart rates was greater in Gly49 (rs1801252G) and in Arg389 (rs1801252C) carriers compared with the more frequent Ser49 (rs1801252A) and Gly389 (rs1801252G) alleles."	Allele G is associated with increased response to carvedilol in healthy individuals as compared to allele A.	21599570	1451094340
ADRB1	rs1801253	C	metoprolol	efficacy	yes	The authors used the dose of metoprolol prescribed, the resting heart rate and survival analysis to determine drug response. They do not report on the Ser49Gly (rs1801252) in this study.	Allele C is not associated with increased response to metoprolol in people with Heart Failure as compared to allele G.	12921807	827567370
ADRB1	rs1801253	CG + GG	atenolol	efficacy	yes	Reported as Gly389 carriers being more likely to respond favorably to ventricular rate control therapy and requiring the lowest doses of rate control medication compared to Arg389Arg (60 % vs 51 %). GC SNP; be careful. Gly corresponds to G on the + strand. [stat_test: chi square].	Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.	22192668	827816261
ADRB1	rs1801252	AA	metoprolol	efficacy	yes	Significant association between BP response to metoprolol and this variant was not found, though there was a trend towards association(p = 0.08). But when analyzed as part of a haplotype with Arg389Gly, there was a significant association with diastolic BP(no response vs. reduction of 14.7 mmHg). Ambulatory blood pressure is what was analyzed. There were no GG.	Genotype AA is associated with increased response to metoprolol in people with Hypertension as compared to genotype AG.	12844134	981239992
ADRB1	rs1801252	AA	metoprolol	efficacy	yes	Patients with the AA genotype (homozygous for Ser49) had a more significant decrease in systolic blood pressure than patients with the AG genotype (heterozygous for Ser49Gly). Patients with the GG genotype are exceedingly rare, and were not studied. There was no significant difference between patients with the different genotypes in regards to heart rate, diastolic blood pressure or mean arterial pressure. This SNP was also studied in conjunction with rs1801253. While the more influential SNP is rs1801253, patients homozygous for Ser49 (genotype AA) had a greater decrease in systolic blood pressure than those that were heterozygous for Ser49Gly (genotype AG) when the two SNPs were studied together.	Genotype AA is associated with increased response to metoprolol in people with Essential hypertension as compared to genotype AG.	16815314	981476533
ADRB1	rs1801252	A	citalopram	efficacy	no	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (AA, AG, GG) or the alleles (A, G), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	Allele A is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.	18797399	1184749202
ADRB1	rs1801253	G	Beta Blocking Agents	efficacy	yes	The association was only found in patients with coadministration of ß-blockers compared to no ß-blocker use. Coadministered ß-blockers were carvedilol (n = 55), bisoprolol (n = 13), atenolol (n = 9), nadolol (n=4), metoprolol (n=3), and propranolol (n=3).	Allele G is associated with decreased response to Beta Blocking Agents and flecainide in people with Tachycardia as compared to allele C.	27500822	1448257049
ADRB1	rs1801253	CC	metoprolol	efficacy	yes	Patients with the CC genotype (homozygous for Arg389) had a more significant decrease in systolic blood pressure, diastolic blood pressure, and mean arterial pressure than patients with the GG genotype (homozygous for Gly389). Patients with the CG genotype (heterozygous for Gly389Arg) had less of a decrease than patients with the CC genotype, but more of a decrease than patients with the GG genotype. There was no significant difference between patients with the different genotypes in regards to heart rate. This SNP was also studied in conjunction with rs1801252. However, the influence from rs1801252 is small compared to the influence from rs1801253. This study showed that patients with one or more G allele did not respond to metoprolol and were classified as non-responders, while patients homozygous for the C allele had a good response and thus are labeled good responders.	Genotype CC is associated with increased response to metoprolol in people with Essential hypertension as compared to genotypes CG + GG.	16815314	981476550
ADRB1	rs1801253	CC	metoprolol	efficacy	yes	This SNP was presented as ADRB1 Arg389Gly. Subjects were given dobutamine with and without metoprolol pre-treatment in order to evaluate this SNPs effect on responsiveness to beta-blocker treatment. The increase in fractional shortening (FS) due to dobutamine was greater in subjects homozygous for the Arg allele as compared to Gly carriers. Similarly, subjects homozygous for the Arg allele showed significant blunting of dobutamine-induced increase of FS when pre-treated with metoprolol, down to levels comparable to untreated Gly carriers. Gly carriers saw very little blunting of the effects due to dobutamine when pre-treated with metoprolol.	Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotypes CG + GG.	21311897	1043859504
ADRB1	rs1801253	C	carvedilol	efficacy	yes	"The ADRB1 Gly49 allele was associated with higher baseline heart rates. Carvedilol-induced reduction of exercise heart rates was greater in Gly49 (rs1801252G) and in Arg389 (rs1801252C) carriers compared with the more frequent Ser49 (rs1801252A) and Gly389 (rs1801252G) alleles."	Allele C is associated with increased response to carvedilol in healthy individuals as compared to allele G.	21599570	1451094360